Tag

Tysabri

All articles tagged with #tysabri

health1 year ago•3 min saved

Long-term Tysabri use shows sustained disease inactivity in patients

A study from Hungary found that a majority of relapsing-remitting multiple sclerosis (RRMS) patients treated with Tysabri (natalizumab) experienced no evidence of disease activity (NEDA-3) for up to six years. The study, involving 121 patients, showed that 80.2% reached NEDA-3, with the highest rate in the first year. Tysabri stabilized dexterity, walking function, and improved cognition, while maintaining quality of life. Patients with lower disability scores were more likely to achieve NEDA-3, and those previously on injectable therapies were less likely to reach this outcome.

via Multiple Sclerosis News Today|

#cognitive-function #disease-progression #health

health2 years ago•4 min saved

"Long-Term Neurologic Effects of Tysabri-Induced PML in Multiple Sclerosis Patients"

A study in Austria found that people with multiple sclerosis (MS) who develop progressive multifocal leukoencephalopathy (PML) as a side effect of Tysabri often experience worsening neurological symptoms and disability progression over time. Most disability progression occurs without disease relapses or inflammatory activity in the brain. The study highlights the devastating impact of PML and the need to avoid it. Tysabri, an antibody-based therapy for MS, is known to increase the risk of PML, a rare brain infection caused by the John Cunningham virus. Strict monitoring is required for patients on Tysabri to detect and control PML.

via Multiple Sclerosis News Today|

#disability #health #multiple-sclerosis

health2 years ago•4 min saved

FDA Approves Groundbreaking Biosimilar for Multiple Sclerosis Treatment

The FDA has approved Tyruko, the first biosimilar to Tysabri, for the treatment of adults with relapsing forms of multiple sclerosis (MS). Tyruko is also indicated for treating moderately to severely active Crohn's Disease. Biosimilars are highly similar to already approved biological products and offer additional treatment options for patients. The approval of Tyruko is based on evidence showing no clinically meaningful differences in safety and effectiveness compared to Tysabri. However, both medications carry a boxed warning about the increased risk of progressive multifocal leukoencephalopathy (PML), a viral infection of the brain.

via FDA.gov|

#biosimilar #fda #health